Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Japan Doctors’ Lobby Braced for Tough Social Security Debate after Election
June 20, 2019
- Generic Share Hits Plateau after Reaching 70%: FPMAJ Pharmacy Survey
June 17, 2019
- Don’t Expand Comparator PMP Removal Rule, Set Deduction Limit for Method II: FPMAJ
June 17, 2019
- Discuss Cost Effectiveness Assessment, Disclosure Ratios Separately: FPMAJ
June 17, 2019
- FPMAJ Calls for Post-Launch Premiums for Add’l Indications, Evidence
June 17, 2019
- Fix Price Maintenance Premium to Make It Fit Its Concept, Revisit Product/Company Criteria: FPMAJ
June 17, 2019
- JPMA Nudges PMDA to Increase Int’l Staffers, Drive Harmonization in Asia
June 12, 2019
- Doctors’ Lobby Voices Opposition to Changing Health Coverage, Copay Rates for Minor Illnesses
June 6, 2019
- Ahead of G20 Summit, Global Pharma Leaders Prod PM Abe to Take Leadership in Addressing Health Challenges
June 5, 2019
- Generic Industry Calls for Support for API Purchase Cost, Revision of Gx Pricing: LDP Study Group
June 3, 2019
- JPMA Asks Govt to Buy 1.3 Billion Yen Cryo-EM Equipment to Fuel Drug Discovery
May 29, 2019
- JPWA Pushing for September Announcement of New NHI Prices
May 27, 2019
- Medipal Pres. Watanabe Elected as New JPWA Chief
May 24, 2019
- Professor Calls for More Balanced Healthcare Resource Allocation, Higher Copay for Minor Illnesses
May 24, 2019
- Hodanren Renews Call for Transparent Pricing for Kymriah
May 23, 2019
- OTC Industry Group to Up Its Efforts to Reduce “Switch Lag”
May 22, 2019
- Sales of Japan CRO Association Members Down 1.2% to 190 Billion Yen in 2018; Pharma Sales Up 2.6%
May 22, 2019
- Wholesaler Group to Set Up Own Rules for Information Provision by Autumn
May 21, 2019
- Kymriah’s 33.5 Million Yen Price Tag Favorably Received by JMA
May 16, 2019
- Payer Reps Stress Need to Revise Coverage of Drugs for Minor Illnesses; Kymriah’s Price Isn’t Necessarily too High
May 16, 2019
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…